Abstract

Antimicrobial resistance (AMR) and healthcare associated infections pose a significant threat globally. One key prevention strategy is to follow antimicrobial stewardship practices, in particular, to maximise targeted oral therapy and reduce the use of indwelling vascular devices for intravenous (IV) administration. Appreciating when an individual patient can switch from IV to oral antibiotic treatment is often non-trivial and not standardised. To tackle this problem we created a machine learning model to predict when a patient could switch based on routinely collected clinical parameters. 10,362 unique intensive care unit stays were extracted and two informative feature sets identified. Our best model achieved a mean AUROC of 0.80 (SD 0.01) on the hold-out set while not being biased to individuals protected characteristics. Interpretability methodologies were employed to create clinically useful visual explanations. In summary, our model provides individualised, fair, and interpretable predictions for when a patient could switch from IV-to-oral antibiotic treatment. Prospectively evaluation of safety and efficacy is needed before such technology can be applied clinically.

The decision to switch patients from intravenous to oral antibiotic therapy is important for the individual and wider society. Here, authors show a machine learning model using routine clinical data can predict when a patient could switch.

Details

Title
Personalising intravenous to oral antibiotic switch decision making through fair interpretable machine learning
Author
Bolton, William J. 1   VIAFID ORCID Logo  ; Wilson, Richard 2 ; Gilchrist, Mark 3 ; Georgiou, Pantelis 4 ; Holmes, Alison 5 ; Rawson, Timothy M. 6   VIAFID ORCID Logo 

 Imperial College London, Centre for Antimicrobial Optimisation, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); Imperial College London, AI4Health Centre for Doctoral Training, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); Imperial College London, Department of Computing, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); Imperial College London, National Institute for Health Research, Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111) 
 Imperial College London, Centre for Antimicrobial Optimisation, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); Imperial College London, National Institute for Health Research, Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); University of Liverpool, Faculty of Health & Life Sciences, Liverpool, UK (GRID:grid.10025.36) (ISNI:0000 0004 1936 8470) 
 Imperial College London, Centre for Antimicrobial Optimisation, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); Imperial College London, National Institute for Health Research, Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); Imperial College Healthcare NHS Trust, London, UK (GRID:grid.417895.6) (ISNI:0000 0001 0693 2181) 
 Imperial College London, Centre for Antimicrobial Optimisation, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); Imperial College London, National Institute for Health Research, Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); Imperial College London, Centre for Bio-inspired Technology, Department of Electrical and Electronic Engineering, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111) 
 Imperial College London, Centre for Antimicrobial Optimisation, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); Imperial College London, National Institute for Health Research, Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); University of Liverpool, Faculty of Health & Life Sciences, Liverpool, UK (GRID:grid.10025.36) (ISNI:0000 0004 1936 8470); Imperial College London, Department of Infectious Diseases, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111) 
 Imperial College London, Centre for Antimicrobial Optimisation, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); Imperial College London, National Institute for Health Research, Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111) 
Pages
506
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2913782287
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.